Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023
-- Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance --…
Wugen Announces CEO Transition
-- Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer -- ST. LOUIS, MO and SAN DIEGO, CA, March…
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,…
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design